〔Abstract〕 Objective To investigate the clinical effect of tegio capsule combined with carrelizumab on stage Ⅲ-Ⅳ gastric cancer. Methods 60 patients with advanced gastric cancer who refused intravenous chemotherapy in Kangmei Hospital from March 2020 to May 2021 were selected. According to the random number table method, they were divided into control group and observation group, with 30 cases in each group. The control group was treated with tegio capsule, and the observation group was treated with tegio capsule combined with carrelizumab. The clinical treatment effect, the score changes of quality of life assessment scale (SF-36) before and after treatment and the incidence of adverse reactions during treatment were compared between the two groups. Results The disease control rate in the observation group was 63.33%, which was significantly higher than 36.67% in the control group (P < 0.05). After treatment, the each dimension scores of SF-36 scales in the observation group were significantly higher than those in the control group (P < 0.05). During the treatment period, the incidence of adverse reactions in the observation group was 46.67%, which was significantly higher than 26.67% in the control group (P < 0.05), but the main manifestations were immune related adverse events, mainly mild to moderate, which were improved after taking corresponding measures. Conclusion Carrilizumab combined with tegio capsule has significant clinical efficacy in the treatment of stage Ⅲ-Ⅳ gastric cancer, which can effectively control the disease progression and improve the quality of life of patients, and most of the adverse reactions are mild to moderate.